Background. Hepatic steatosis, a common histological findin in hepatitis C virus (HCV)-infected patients, is associated with severity of fib osis. The prevalence and significanc of steatosis in patients coinfected with human immunodeficienc virus (HIV) and HCV are not well characterized.
. Patients with HIV and HCV coinfection have an accelerated course of progression to cirrhosis and endstage liver disease, compared with that in patients with HCV infection alone [4] [5] [6] [7] . As a consequence, end-stage liver disease resulting from HCV infection is now a common cause of death in HIV-infected persons in developed countries [8] [9] [10] . Because the treatment of HCV in the setting of HIV coinfection often does not result in a sustained virological response, it is important to identify the risk factors affecting the progression of liver disease that are potentially modifiable
The reasons for the increased risk of progression of liver fib osis in coinfected patients are not well understood. Studies have found associations with advancing age, alcohol consumption, and low CD4 + cell count [11, 12] . Hepatic steatosis, a frequent histopathologic findin on liver biopsy in the setting of HCV infection, has been identifie as an additional risk factor for the progression of fib osis in HIV-uninfected patients with HCV infection. Its prevalence, severity, and impact on liver disease in the setting of HIV infection have not been adequately studied. Risk factors that have been elucidated for steatosis in HIVuninfected patients with HCV infection include viral factors, such as HCV genotype 3, and host factors, such as an elevated body-mass index (BMI), visceral obesity, and possibly alcohol use, insulin resistance, and lipid abnormalities [13] [14] [15] [16] [17] [18] [19] [20] [21] . Antiretroviral therapy may predispose HIV-infected patients toward the development of some of these risk factors. In particular, visceral obesity, which has been associated epidemiologically with the use of protease inhibitors (PIs), may be a component of the lipodystrophy syndrome seen in patients with HIV infection. Certain HIV PIs also appear to cause insulin resistance and hyperlipidemia [22] [23] [24] . Furthermore, hepatic steatosis in association with hyperlactatemia or lactic acidosis is a rare complication of therapy with nucleoside reverse-transcriptase inhibitors, likely as a result of mitochondrial toxicity [25] . Taken together, these observations suggest that patients with HIV and HCV coinfection could be predisposed toward developing hepatic steatosis, which could adversely affect fib osis.
To study the relationships among HIV and HCV disease status, antiretroviral therapy, and metabolic complications associated with HIV and its therapy, we conducted a retrospective study of patients with HIV and HCV coinfection attending an urban HIV clinic. The objectives of the study were to determine whether the presence of hepatic steatosis is associated with more-advanced histological finding on liver biopsy and to identify potential risk factors for steatosis in patients with HIV and HCV coinfection.
PATIENTS AND METHODS
Study population. The present study included patients coinfected with HIV and HCV from the 2 HIV clinics (the Centers for Special Studies) of the New York Presbyterian HospitalWeill Cornell Center, which serve a diverse population of ∼1800 HIV-infected patients. An electronic database contains information on ∼8000 patients, including past and present clinic patients. Patients with documented HIV and HCV infection who underwent liver biopsy between January 1998 and June 2003 who had electronic medical records and liver-biopsy specimens available were included in the study. Patients who underwent fin needle aspirate only or who had an HCV RNA level below the assay limit of detection, history of treatment of HCV infection before liver biopsy, diagnosis of hepatoma, or hepatitis B virus infection (surface antigen or DNA positive) were excluded. The indication for liver biopsy for all remaining subjects was the evaluation of HCV disease.
Histological evaluation. An experienced liver pathologist (L.M.P.) who was unaware of the clinical characteristics of patients evaluated and graded the liver-biopsy samples with the hepatitis scoring system described by Scheuer [26] and the steatosis and steatohepatitis scoring system described by Brunt et al. [27] . The hepatitis scoring system included necroinflamma tory grade (0-4) and fib osis stage (0-4). Steatosis was graded on the basis of the percentage of hepatocytes with macrovesicular steatosis: grade 0, no steatosis; grade 1, 1%-33%; grade 2, 34%-66%; grade 3, 166%. In addition, histological features that are characteristic of steatohepatitis (and not viral hepatitis) were assessed and graded in the following manner, as described by Brunt et al. [27] : hepatocellular ballooning and disarray (none, mild, or marked), intra-acinar (lobular) inflammatio (graded 0-3 on the basis of inflammato y foci per 20ϫ field) and pericellular fib osis (graded 0-3 on the basis of percentage of zone 3 foci involved).
Variables examined. + cell count, and HIV RNA level at time of biopsy (with a limit of detection of !400 or !50 copies/mL as available), nadir CD4 + cell count, HCV genotype, and HCV RNA level. Information on antiretroviral regimen(s) and duration was collected. Lipodystrophy, define as the presence of lipoatrophy or lipoaccumulation, was based on documentation in the medical record as reported by either the patient or the provider. Alcohol use was elucidated from patients' medical records as well as from a questionnaire completed at the time of initial evaluation in the hepatology clinic. It was quantifie as none, mild to moderate, or heavy and was qualifie as past or present use. Lipid and glucose levels did not necessarily reflec fasting specimens. Clinical characteristics potentially related to steatosis, such as diabetes mellitus, were also ascertained. The study was approved by the Institutional Review Board of the Committee on Human Rights in Research at Weill Cornell Medical College (New York, NY).
Statistical analysis. The hepatitis inflammato y grade and fib osis stage as well as other histological finding were compared across the level of steatosis with Spearman's rank correlation coefficien and by ordinal logistic regression. Because few patients had advanced grades of steatosis, grades 2 and 3 were combined for statistical analysis. This resulted in 3 categories of steatosis: no steatosis (grade 0), mild steatosis (grade 1), and moderate to severe steatosis (grade 2-3). An exploratory analysis was done to identify clinical characteristics associated with steatosis and fib osis using the nonparametric MannWhitney U test (for dichotomous predictor variables), Spear- man's rank correlation coefficien (for ordinal or continuous predictor variables), and the Kruskal-Wallis test (for multicategory predictor variables). Odds ratios (ORs) with 95% confidenc intervals (CIs) were calculated by ordinal logistic regression with steatosis or fib osis categories as the response (dependent) variables. These ORs approximated the risk of having a steatosis or fib osis grade that is 1 category higher as a result of the define increase in a continuous independent variable or a change from "no" to "yes" in a dichotomous independent variable. Multivariate analysis was done by ordinal logistic regression with forward, stepwise regression; the entry criterion into the model was . All covariates used in the models met the assumption P р .2 of parallel regression [28] . HIV RNA levels below the level of detection (!400 or !50 copies/mL) were assigned values of 400 and 50, respectively, before log transformation. Histological scores that fell between 2 scores were uniformly rounded to the higher value; for example, fib osis stage 1-2 was recorded as 2. Data were analyzed with STATA software (version 7.0; STATA).
RESULTS
Of 1279 patients identifie as being positive for HCV antibody and/or RNA, 143 had liver biopsies done between January 1998 and June 2003. Thirty-seven patients were excluded for the following reasons: fin needle aspirate only (3), positive for hepatitis B surface antigen (6), negative for HCV RNA (2), interferon therapy predating biopsy (9), incomplete medical record (7), and unavailable liver-biopsy slides (10); this left 106 evaluable patients. Table 1 summarizes characteristics of patients at the time of liver biopsy and histological findings
The distribution of macrovesicular steatosis was as follows: grade 0 (none), 44%; grade 1 (mild), 47%; grade 2 (moderate), 7%; grade 3 (severe), 2%. Only 16 biopsy samples showed microvesicular steatosis: 15 showed grade 1, and 1 showed grade 3. With the exception of 1 patient (grade 1), all patients with microvesicular steatosis had very similar grades of macrovesicular steatosis.
Relationship between steatosis and histological features of HCV infection and steatohepatitis. Fibrosis stage was associated with the severity of steatosis (OR, 1.84 [95% CI, 1.06-3.20];
). There was no association between necroin-P p .031 flammato y activity and the severity of steatosis (OR, 0.89 [95% CI, 0.49-1.62];
). We observed a trend between the P p .71 severity of steatosis and increased pericellular fib osis, a pattern of fib osis that is known to be associated with steatohepatitis (OR, 1.49 [95% CI, 0.96-3.07];
). The severity of stea-P p .07 tosis was not associated with albumin, total bilirubin, transaminase, a-fetoprotein, or HCV RNA levels.
Association between clinical characteristics and the severity of steatosis. In univariate analyses, HCV genotype 3 was the strongest predictor of severity of steatosis (OR, 14.9 [95% CI, 2.03-109.71]; ) (table 2) . There was no association P p .0008 between duration (in months) of particular types of antiretroviral therapy (e.g., PIs and stavudine) and steatosis. The only significan association between steatosis and antiretroviral ther- a Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by ordinal logistic regression. Steatosis was categorized as none, mild, or moderate to severe. ORs approximate the risk of having a steatosis grade that is 1 category higher as a result of the defined increase in a continuous independent variable or a change from "no" to "yes" in a dichotomous independent variable. b Information was available for all patients with the exception of the following variables: race (1 patient), BMI (5 patients), total cholesterol level (3 patients),
HDL and non-HDL cholesterol levels (13 patients), triglyceride levels (12 patients), alcohol use (10 patients), years since HIV diagnosis (1 patient), and HCV genotype (5 patients). c Forward, stepwise ordinal logistic regression was done. The covariates race, nadir CD4 + cell count, and NNRTI use at the time of biopsy had and P 1 .20 were removed from the model. Because of significant overlap in the covariates lipoatrophy and lipodystrophy, only lipodystrophy was included in the model. Because of missing information (particularly HDL cholesterol), the sample size included in multivariate analysis decreased to 84 patients. apy was a negative association between use of nonnucleoside reverse-transcriptase inhibitors (NNRTIs) at the time of biopsy and severity of steatosis, which was significan in univariate analyses only. In multivariate analysis, greater BMI, the presence of lipodystrophy (lipoatrophy or lipoaccumulation), and lower levels of high-density lipoprotein (HDL) cholesterol were significantl associated with severity of steatosis (table 2), whereas genotype 3 no longer was significantl associated with steatosis.
Association of clinical characteristics with stage of fib osis. In multivariate analysis, increasing hepatitis necroinflammato y activity and lipodystrophy each was associated with more severe fib osis (table 3) . In contrast, patients of African American descent had less-severe fib osis than did patients of other races/ ethnicities. The severity of steatosis, which was associated with fib osis in univariate analyses, remained positively associated with severity of fib osis in multivariate analysis, although this findin was no longer statistically significan ( ). The history or P p .10 duration of antiretroviral therapies was not associated with fi brosis in univariate or multivariate analyses (data not shown).
DISCUSSION
The high prevalence of steatosis observed in the present study (56%) is consistent with other studies in patients coinfected with HCV and HIV (steatosis frequencies of 40%-67%) [29] [30] [31] and HCV-monoinfected patients (30%-70%) [13-15, 17-20, 32] . The prevalence of nonalcoholic fatty liver disease in the general population is estimated at 10%-15% among persons a Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by ordinal logistic regression. ORs approximate the risk of having a fibrosis grade that is 1 category higher as a result of a 1-unit increase in a continuous independent variable or a change from "no" to "yes" in a dichotomous independent variable. b Information was available for all patients with the exception of the following variables: race (1 patient), BMI (4 patients), total cholesterol level (3 patients),
HDL and non-HDL cholesterol levels (13 patients), alcohol use (10 patients), years since HIV diagnosis (1 patient), and genotype (5 patients). c Forward, stepwise ordinal logistic regression was done. The covariates diabetes and total cholesterol had and were removed from the model. P 1 .20 of normal weight [33] , which suggests that the frequency of steatosis is significantl increased in the setting of HIV and HCV coinfection. Whether this increase is related to HCV infection, HIV infection or treatment, or other causes is not yet known. We observed moderate-to-severe steatosis in only 7% of biopsy specimens from coinfected patients, which is similar to the 4%-5% prevalence described in a large study of patients from North America who were monoinfected with HCV, where HCV genotype 1 predominates [34] . Other surveys of HCVmonoinfected patients, however, have found higher prevalences of severe steatosis of 8%-23% [13-15, 17-20, 32] . The reasons for these discrepant finding are uncertain, but regional variations in genotype distribution may contribute.
We found that the severity of steatosis on liver biopsy was associated with more-advanced fib osis, whereas necroinflam mation was not. In multivariate analysis, this association between steatosis and fib osis only approached statistical significanc ( ). Because, for unknown reasons, a lower P p .10 prevalence of steatosis has been observed in the setting of cirrhosis in studies of HCV-monoinfected patients and with nonalcoholic fatty liver disease [19, 32, 35, 36] , we repeated the multivariate analysis excluding the 7 patients with cirrhosis. This yielded a statistically significan association between steatosis and fib osis stage (data not shown; OR, 2.14;
). P p .025 Multiple studies of HCV-monoinfected patients have documented a similar association between steatosis and fib osis [13, [17] [18] [19] 37] . Proposed mechanisms by which steatosis may increase fib osis in the setting of HCV infection are similar to those proposed for nonalcoholic fatty liver disease. In the setting of steatosis, the addition of oxidative stress from mitochondrial toxicity or viral inflammato y response may lead to lipid peroxidation and the release of proinflammato y and profib otic cytokines [38] . Other possible contributors include cytokine release due to hyperinsulinemia and/or effects of the adipocyte-derived hormone leptin. It is not known whether the etiology of steatosis affects the association with fib osis.
We identifie plausible risk factors for steatosis in coinfected patients, including increasing BMI, decreasing HDL cholesterol, and the presence of lipodystrophy. Elevated BMI is a wellestablished risk factor for nonalcoholic fatty liver disease as well as for HCV-associated steatosis in HCV-monoinfected patients, particularly of genotype 1. The association between BMI and steatosis is thought to be due to insulin resistance and hyperinsulinemia [38] . Because of our retrospective design, we could not evaluate insulin resistance; however, neither random serum glucose level determinations nor the presence of diabetes was found to be associated with severity of steatosis.
We also found that lower HDL cholesterol levels were associated with increasing severity of steatosis; however, total cholesterol and non-HDL cholesterol levels were not. The use of lipid-lowering medications is unlikely to be a confounding factor, because only 3 patients in our study were being treated for hypercholesterolemia. Dyslipidemia, particularly increased total cholesterol and triglyceride levels, is a known risk factor for nonalcoholic fatty liver disease, although its contribution to HCV-related steatosis has not been well studied.
The presence of lipodystrophy, define here as lipoatrophy and/or lipoaccumulation, was associated with steatosis in mul-tivariate analysis. Although our assessment of lipodystrophy was limited, there is biological plausibility for the association with steatosis. Visceral obesity, along with increased BMI, has been shown to be a risk factor for steatosis in HCV-monoinfected patients. The association of lipoatrophy with insulin resistance and/or mitochondrial toxicity offers an additional potential biological mechanism for the development of steatosis. In support of this contention, a recent small study showed that steatosis was found on liver-biopsy samples from 5 of 9 HIVinfected patients with lipodystrophy and abnormal transaminase levels (in the absence of viral hepatitis) [39] .
Although lipodystrophy was associated with steatosis in our study, particular antiretroviral therapies were not. In general, steatosis was less advanced in patients receiving antiretroviral therapy; however, this was significan only for NNRTI use in univariate analyses. This inverse association may be explained by certain features of NNRTIs: they are not known to cause insulin resistance and are frequently associated with significan elevations in HDL cholesterol levels [40] . Another preliminary study in coinfected patients showed a similar protective effect of NNRTI use on steatosis in univariate analyses [31] . We found no association between steatosis and PI or stavudine use, in contrast to a study of 113 patients coinfected with HIV and HCV that found an association with prior stavudine use [30] .
The 4 patients infected with HCV genotype 3 in our study had steatosis (2 mild and 2 moderate to severe), and genotype 3 was strongly associated with steatosis in univariate analyses, although it did not remain significan in multivariate analysis, perhaps because of limited statistical power. This association has been demonstrated clearly in HCV-monoinfected patients; it is thought to result from a direct viral effect of HCV [14] .
Although we did not observe an association between necroinflammatio and steatosis, necroinflammatio was strongly associated with fib osis, as has been consistently seen in studies of HCV-monoinfected patients. Other risk factors for fib osis seen in multivariate analysis included race and the presence of lipodystrophy. The association between African American race and reduced fib osis does not appear to be due to confounding factors, because African American patients had baseline characteristics similar to those of white and Hispanic patients (data not shown). Furthermore, similar finding were described in a study of HCV-monoinfected patients [41] . In contrast, the impact of lipodystrophy on fib osis has not been previously reported, and whether it may affect fib osis through mechanisms other than insulin resistance or steatosis needs further study.
The limitations of our study include the inability to consistently obtain fasting measurements of lipids and glucose and the nonstandardized assessments of the lipodystrophy and metabolic syndromes. The generalizability of our results may be limited by a selection bias, because the study consisted of patients from a single center who were referred for the evaluation of HCV-related liver disease and underwent liver biopsy. However, our patient population is diverse, with significan numbers of women, African Americans, and Hispanics represented.
In summary, our results suggest that hepatic steatosis is common in patients coinfected with HIV and HCV and that it is associated with more advanced fib osis. Of note, we found that steatosis was associated with potentially modifiabl risk factors that are prevalent in HIV-infected patients, such as low HDL cholesterol levels and lipodystrophy, as well as traditional risk factors, such as BMI. Further investigation into the mechanism, impact, and reversibility of steatosis in patients coinfected with HIV and HCV is warranted, given that steatosis may worsen the progression of HCV-related fib osis, increase the risk of hepatocellular carcinoma [42] , and worsen the treatment prognosis of HCV infection [43] .
